An increase in the number of advanced biotechnology and pharmaceutical discovery programs is expected to drive Viral Vector and Plasmid Manufacturing market investment. Approximately 70% of these therapies, there are over 700 cell and gene therapies in clinical trials, and vectors. The production rate was therefore surpassed by demand for the vectors. Substantial investments are...